Hemostasis Today

July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
William Aird: Was Hematology–Oncology an Inevitable Partnership?
Jul 5, 2026, 13:15

William Aird: Was Hematology–Oncology an Inevitable Partnership?

William Aird, Professor of Medicine at Harvard Medical School, shared a post on LinkedIn:

“A Match Made In… History?

Why hematology-oncology?

Why not urology-oncology?

Or GI-oncology?

It sounds like a joke. Maybe it shouldn’t.

In the U.S., hematology and oncology are treated as a natural pair. But the pairing was never written into biology.

If patient overlap alone determined specialty marriages, the map would look different.

Urologic cancers: more than half a million new U.S. diagnoses a year.

GI cancers: roughly 370,000.

Breast cancer: over 300,000.

Leukemia, lymphoma, and myeloma combined: about 190,000.

So patient volume cannot be the whole answer.

The answer lies, at least in part, in history — especially in the United States:

The contested borderland of leukemia, lymphoma, chemotherapy, marrow failure, transfusion, and bone marrow transplantation, which gradually became shared clinics, shared treatments, shared training, shared boards, and shared identity.

And yet the two fields still feel different.

Hematology leans diagnostic: What is the pattern? What is the mechanism — inherited, immune, nutritional, reactive, clonal, marrow-based, peripheral?

Oncology leans therapeutic: What is the stage? The target? The regimen? The sequence? The trial?

An oversimplification, of course. Hematologists treat. Oncologists diagnose. Blood cancers belong fully to both.

But specialties are not natural laws. They are historical settlements — useful, sometimes elegant, sometimes awkward.

If we organized medicine today from first principles rather than inherited precedent, would we still pair hematology with oncology?”

Other posts featuring William Aird on Hemostasis Today.